Sutro Biopharma, Inc. (STRO)

Sutro Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	70.14	48.13	31.29	207.02	4.98
Short-Term Investments	306.35	287.11	167.52	161.99	112.9
Cash & Cash Equivalents	376.49	335.24	198.81	369.01	117.88
Cash Growth	12.31%	68.62%	-46.12%	213.04%	-42.36%
Receivables	36.08	7.12	12.45	5.56	6.3
Other Current Assets	8.97	10.8	7.25	3.61	4.39
Total Current Assets	421.54	353.15	218.52	378.18	128.57
Property, Plant & Equipment	44.76	51.06	51.59	12.94	9.63
Long-Term Investments	0	0	68.78	0	15.61
Other Long-Term Assets	4.44	2.73	2.53	2.99	2.56
Total Long-Term Assets	49.19	53.79	122.89	15.93	27.8
Total Assets	470.74	406.94	341.41	394.11	156.37
Accounts Payable	9.44	4.8	6.01	5.54	5.58
Deferred Revenue	74.05	106.64	5.5	20.7	35.66
Current Debt	10.48	17.09	10.41	0	1
Other Current Liabilities	-0.22	-61.98	19.82	3.35	-9.28
Total Current Liabilities	93.75	66.55	41.74	29.6	32.97
Long-Term Debt	23.15	33.35	46.96	24.55	8.88
Other Long-Term Liabilities	204.19	90	0.15	7.92	16.74
Total Long-Term Liabilities	227.34	123.35	47.11	32.47	25.61
Total Liabilities	321.09	189.9	88.84	62.06	58.58
Total Debt	33.64	50.43	57.37	24.55	9.88
Debt Growth	-33.30%	-12.10%	133.75%	148.53%	-32.93%
Retained Earnings	-559.41	-452.62	-333.41	-227.87	-195.75
Comprehensive Income	0.02	-0.62	-0.31	0.13	0.17
Shareholders' Equity	149.65	217.05	252.56	332.05	97.79
Net Cash / Debt	342.86	284.81	141.44	344.46	108
Net Cash / Debt Growth	20.38%	101.37%	-58.94%	218.94%	-43.09%
Net Cash Per Share	5.70	5.61	3.07	10.57	4.70
Working Capital	327.8	286.61	176.78	348.59	95.6
Book Value Per Share	2.49	4.28	5.48	10.19	4.26

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).